Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade

International Journal of Oncology

Volumn 34, Issue 1, 2009, Pages 79-87

  Huang, Jianzhong ^a   Bae, Jae O ^a   Tsai, Judy P ^a   Kadenhe Chiweshe, Angela ^a   Papa, Joey ^a   Lee, Alice ^a   Zeng, Shan ^a   Kornfeld, Z Noah ^a   Ullner, Paivi ^a   Zaghloul, Nibal ^a   Ioffe, Ella ^b   Nandor, Sarah ^b   Burova, Elena ^b   Holash, Jocelyn ^b   Thurston, Gavin ^b   Rudge, John ^b   Yancopoulos, George D ^b   Yamashiro, Darrell J ^a   Kandel, Jessica J ^a,c  

^a Columbia University ^*  (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c Children's Hospital 214N   (United States)

Author keywords

Angiogenesis; Angiopoietin 1; Tie 2; Tumor growth; Vascular remodeling; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN 1; TETRAMER; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOPOIETIN RECEPTOR; ANGPT1 PROTEIN, HUMAN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL STRESS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION; ANIMAL; CELL HYPOXIA; CYTOLOGY; DRUG ANTAGONISM; EWING SARCOMA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; KIDNEY TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION; WESTERN BLOTTING; XENOGRAFT;

ANGIOPOIETIN-1; ANIMALS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RECEPTOR, TIE-2; SARCOMA, EWING'S; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60749124285     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000131     Document Type: Article

References (32)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
2. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003.
3. Benjamin LE, Hemo I and Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598, 1998.
4. Benjamin LE, Golijanin D, Itin A, Pode D and Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999.
5. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ and Kandel JJ: Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2: 36-42, 2004.
6. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A and Vajkoczy P: Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18: 338-340, 2004.
7. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005.
8. Gerber HP, Kowalski J, Sherman D, Eberhard DA and Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258, 2000.
9. Stoeltzing O, Ahmad SA, Liu W, McCarty MF, Wey JS, Parikh AA, Fan F, Reinmuth N, Kawaguchi M, Bucana CD and Ellis LM: Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 63: 3370-3377, 2003.
10. Hawighorst T, Skobe M, Streit M, Hong YK, Velasco P, Brown LF, Riccardi L, Lange-Asschenfeldt B and Detmar M: Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. Am J Pathol 160: 1381-1392, 2002.
11. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E and Plate KH: Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 165: 1557-1570, 2004.
12. Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, Takagi H, Honda Y, Wiegand SJ, Yancopoulos GD and Nishikawa S: Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest 110: 1619-1628, 2002.
13. Baluk P, Lee CG, Link H, Ator E, Haskell A, Elias JA and McDonald DM: Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. Am J Pathol 165: 1071-1085, 2004.
14. Zhou YF, Stabile E, Walker J, Shou M, Baffour R, Yu Z, Rott D, Yancopoulos GD, Rudge JS and Epstein SE: Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor. J Am Coll Cardiol 44: 897-903, 2004.
15. Sandhu R, Teichert-Kuliszewska K, Nag S, Proteau G, Robb MJ, Campbell AI, Kuliszewski MA, Kutryk MJ and Stewart DJ: Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat. Cardiovasc Res 64: 115-124, 2004.
16. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, Di Tomaso E, Munn LL and Jain RK: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563, 2004.
17. Findley CM, Cudmore MJ, Ahmed A and Kontos CD: VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2: 2619-2626, 2007.
18. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ and Kandel JJ: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100: 7785-7790, 2003.
19. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J, Jain V, Bailey K, Karow M, Fandl J, Samuelsson SJ, Ioffe E, Rudge JS, Daly TJ, Radziejewski C and Yancopoulos GD: Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10: 38-44, 2003.
20. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
21. Huang J, Frischer JS, New T, Kim ES, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ and Yamashiro DJ: TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther 3: 335-343, 2004.
22. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD and McDonald DM: Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286: 2511-2514, 1999.
23. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171-1180, 1996.
24. Kim I, Kim HG, So JN, Kim JH, Kwak HJ and Koh GY: Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-Kinase/Akt signal transduction pathway. Circ Res 86: 24-29, 2000.
25. Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, Lai KM, Lin HC, Ioffe E, Yancopoulos GD and Rudge JS: Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 18: 1060-1071, 2004.
26. Iivanainen E, Nelimarkka L, Elenius V, Heikkinen SM, Junttila TT, Sihombing L, Sundvall M, Maatta JA, Laine VJ, Yla-Herttuala S, Higashiyama S, Alitalo K and Elenius K: Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J 17: 1609-1621, 2003.
27. Holash J, Wiegand SJ and Yancopoulos GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18: 5356-5362, 1999.
28. Holash J, Maisonpierre PC, Compton D, Boland CR, Alexander D, Yancopoulos GD and Weigand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284: 1994-1998, 1999.
29. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
30. Shyu KG, Manor O, Magner M, Yancopoulos GD and Isner JM: Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 98: 2081-2087, 1998.
31. Thurston G, Wang Q, Baffert F, Rudge J, Papadopoulos N, Jean-Guillaume D, Wiegand S, Yancopoulos GD and McDonald DM: Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period. Development 132: 3317-3326, 2005.
32. Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R and McDonald DM: Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94: 984-992, 2004.